General Catalyst led a $72m Series A round in Maxion Therapeutics.

General Catalyst, a venture capital firm, led a $72m Series A round in Maxion Therapeutics, a biotechnology company developing antibody-based drugs, with participation from British Patient Capital, Solasta Ventures, Eli Lilly and Company, LifeArc Ventures, Monograph Capital and BGF. “This landmark fundraising – one of the largest European private biotech financings since the beginning of 2024 – highlights the significant potential of our technology and development pipeline. KnotBodies represent a potential breakthrough biologic drug modality, delivering greater potency, selectivity, and durability. We believe that KnotBodies will provide transformational new therapeutic options for ion channel- and GPCR-driven diseases, across a wide range of therapeutic areas with a remaining high unmet medical need. The calibre of our international investor syndicate validates our approach, and I would like to welcome our new investors to Maxion and thank our existing investors for their continued support,”   Arndt Schottelius, Maxion Therapeutics CEO.